The Efficacy of an Herbal Medicine, Carmint, on the Relief of Abdominal Pain and Bloating in Patients with Irritable Bowel Syndrome: A Pilot Study
- 581 Downloads
Carmint contains total extracts of Melissa officinalis, Mentha spicata, and Coriandrum sativum, which have antispasmodic, carminative, and sedative effects. As abdominal pain/discomfort and bloating are commonly observed in patients with irritable bowel syndrome, we decided to evaluate the effectiveness of Carmint in relieving these symptoms in irritable bowel syndrome patients. We randomly assigned 32 irritable bowel syndrome patients to receive either Carmint or placebo, plus Loperamide or psyllium (based on their predominant bowel function), for 8 weeks. T-test analysis of the results showed that the severity and frequency of abdominal pain/discomfort were significantly lower in the Carmint group than the placebo group at the end of the treatment (P=0.016 and P=0.001, respectively), as were the severity and frequency of bloating (P=0.02 and P=0.002, respectively). This pilot study suggests that Carmint plus loperamide or Carmint plus psyllium (depending on the irritable bowel syndrome subtype) might be effective in these patients.
KeywordsIrritable bowel syndrome Carmint Herbal medicine Randomized placebo-controlled trial
The authors would like to thank POUR SINA pharmaceutical company for providing Carmint and its placebo. This study originated at The Research Center for Gastroenterology and Liver Diseases, Shaheed Beheshti University of Medical Sciences, Tehran, Iran.
- 1.Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA (1999) Functional bowel disorders and functional abdominal pain. Gut 45:43–47Google Scholar
- 2.Watson AR, Bowling TE (2005) Irritable bowel syndrome: diagnosis and symptom management. Br J Commun Nurs 10:118–122Google Scholar
- 7.Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE, Janssens J, Funch-Jensen P, Corazziari E, Richter JE, Koch GG (1993) US householder survey of functional gastrointestinal disorders: Prevalence, sociodemography and health impact. Dig Dis Sci 38:1569–1580PubMedCrossRefGoogle Scholar
- 9.Zuckerman MJ, Guerra LG, Drossman DA, Foland JA, Gregory GG (1995) Comparison of bowel patterns in Hispanic and non-Hispanic whites. Dig Dis Sci 40:1761–1769Google Scholar
- 10.Massarrat S, Saberi-Firoozi M, Soleimani A, Himmelmann GW, Hitzges M, Keshavarz H (1995) Peptic ulcer disease, irritable bowel syndrome and constipation in two populations in Iran. Eur J Gastroentroenterol Hepatol 7:427–433Google Scholar
- 11.Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA (2000) (C) Functional bowel disorders and (D) functional abdominal pain. In: Drossman DA, Talley NJ, Thompson WG, Corazziari E, Whitehead WE (eds). Rome II: The functional gastrointestinal disorders: Diagnosis, pathophysiology and treatment. A multinational consensus, 2nd ed. Degnon Associates, McLean, VA, pp 351–432Google Scholar
- 21.Fleming T (2000) PDR for herbal medicines, 2nd ed. Medical EconomicsGoogle Scholar
- 23.Sweetman SC (2005) Martindale, the complete drug reference, 34th ed. Pharmaceutical Press, p 1749Google Scholar
- 24.Drossman DA (2000) The functional gastrointestinal disorders, their diagnosis and the Rome II process. In: Drossman DA, Talley NJ, Thompson WG, Corazziari E, Whitehead WE (eds). Rome II: The functional gastrointestinal disorders: Diagnosis, pathophysiology and treatment. A multinational consensus, 2nd ed. Degnon Associates, McLean, VA, pp 1–29Google Scholar
- 25.Quartero A, Meineche-Schmidt V, Muris J, Rubin G, de Wit N (2005) Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 18:CD003460Google Scholar